Viral Conjunctivitis Treatment Study

University of Miami

Status: Terminated

Conditions: Viral Conjunctivitis

Treatments: Other: Placebo; Device: 0.01% Hypochlorous acid

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03861728

20170064

Details and patient eligibility

About

The objective of this study is to determine the efficacy Avenova® (0.01% hypochlorous acid) in the treatment of viral conjunctivitis. The investigators hypothesize that patients treated with Avenova® will have a quicker resolution of their ocular signs and symptoms of Viral Conjunctivitis compared with artificial tears.

Enrollment: 11 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients presenting to the Bascom Palmer Eye Institute
• Clinical diagnosis of viral conjunctivitis
• Symptoms less than 1 week duration

Exclusion criteria

• history of allergic conjunctivitis
• history of herpetic eye disease
• concurrent diagnosis of bacterial conjunctivitis (based off microbiology plating)
• Immunocompromised / Immunosuppressed patients
• Patients with HIV
• pregnant women
• prisoners
• adults who are unable to provide consent

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

11 participants in 2 patient groups, including a placebo group

Viral Conjunctivitis Treatment

Experimental group

Description:

Patients with viral conjunctivitis as defined by a + AdenoPlus test and clinical symptoms and signs of viral conjunctivitis who will be treated with 0.01% Hypochlorous acid

Treatment:

Device: 0.01% Hypochlorous acid

Viral Conjunctivitis Placebo

Placebo Comparator group

Description:

Patients with viral conjunctivitis as defined by a + AdenoPlus test and clinical symptoms and signs of viral conjunctivitis who will be treated with Basic Sterile Saline

Treatment:

Other: Placebo